Indaptus Therapeutics, Inc. (INDP) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$3.70

From 52W high−25.26%

Volume1.15M

Market cap$473.01M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$3.70

From 52W high

−25.26%

Volume

1.15M

Market cap

$473.01M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−29.9x

P/E (TTM)

—

RSI (14)

71.9

MomentumView details →

1D Return

−9.67%

YTD Return

+25.09%

SummaryUpdated Jun 1, 2026

Indaptus Therapeutics, Inc. (NASDAQ:INDP) is a pre-clinical biotechnology company founded in 2021 and headquartered in New York, New York. The company was formerly known as Intec Parent, Inc. before changing its name to Indaptus Therapeutics in August 2021. As a development-stage biopharmaceutical company, Indaptus focuses on creating innovative immunotherapy treatments for cancer and viral infections, with its lead candidate currently in Phase I clinical trials.

Ask drillr about Indaptus Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−29.9x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

41.6x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−135.62%

ROA (TTM)

−128.66%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+32.24%

FCF YoY

−1.39%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+52.00%

EBITDA YoY

+9.29%

MomentumView details →

1D Return

−9.67%

YTD Return

+25.09%

1Y Return

+30.94%

RSI (14)

71.9

vs 50D SMA

+95.80%

vs 200D SMA

+63.13%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

19.48x

Quick Ratio

19.48x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.02

EPS Surprise

98.73%

Beats (12Q)

11/12

Next Q EPS Est

−$1.46

Avg Surprise (4Q)

60.97%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−15.42M

Op. CF (TTM)

−15.18M

Next earningsNov 17, 2026 →

Latest newsMore news →

Indaptus Therapeutics, Inc. signed a private placement to issue 20,338,974 shares for aggregate gross proceeds of approximately $24.0 million.10d ago

Tim Ruan resigned as Director of the Board of Directors of Indaptus Therapeutics, Inc., effective September 2, 2026.16d ago

Similar companies

Vogenx Inc.VOGX Eikon Therapeutics, Inc. Common StockEIKN Arcturus Therapeutics Holdings Inc.ARCT Turn Therapeutics Inc.TTRX Puma Biotechnology, Inc.PBYI Genfit S.A.GNFT Find similar companies →

Latest newsMore news →

Indaptus Therapeutics, Inc. signed a private placement to issue 20,338,974 shares for aggregate gross proceeds of approximately $24.0 million.10d ago Tim Ruan resigned as Director of the Board of Directors of Indaptus Therapeutics, Inc., effective September 2, 2026.16d ago